LABORATORY OF IMMUNOLOGY AND BIOLOGY OF METASTASIS

PUBLICATIONS

2012

M. Iezzi, E. Quaglino, A. Amici, P.-L. Lollini, G. Forni & F. Cavallo. DNA vaccination against oncoantigens. A promise. OncoImmunology, in press, 2012.

2011

P.-L. Lollini, G. Nicoletti, L. Landuzzi, F. Cavallo, G. Forni, C. De Giovanni & P. Nanni. Vaccines and other immunological approaches for cancer immunoprevention. Curr. Drug Targets, 12: 1957-1973, 2011. Published online Dec 15, 2010. [Medline]
G. Gasparre, I. Kurelac, M. Capristo, L. Iommarini, A. Ghelli, C. Ceccarelli, G. Nicoletti, P. Nanni, C. De Giovanni, K. Scotlandi, C.M. Betts, V. Carelli, P.-L. Lollini, G. Romeo, M. Rugolo & A.M. Porcelli. A mutation threshold distinguishes the anti-tumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res., 71: 6220-6229, 2011. [Medline]
G. Campadelli-Fiume, C. De Giovanni, V. Gatta, P. Nanni, P.-L. Lollini & L. Menotti. Rethinking herpes simplex virus: the way to oncolytic agents. Rev. Med. Virol., 21: 213-226, 2011. [Medline]
L. Landuzzi, A. Antognoli, G. Nicoletti, S. Croci, A. Palladini, M.L. Ianzano, A. Murgo, V. Stivani, V. Grosso, P. Nanni, C. De Giovanni & P.-L. Lollini. HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. Vaccine, 29: 4690-4697, 2011. [Medline]
M. Pasello, M.C. Manara, F. Michelacci, M. Fanelli, C.M. Hattinger, G. Nicoletti, L. Landuzzi, P.-L. Lollini, A. Caccuri, P. Picci, K. Scotlandi & M. Serra. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal. Cell. Pathol., 34: 131-145, 2011. [Medline]
C. Garofalo, M. C. Manara, G. Nicoletti, M.T. Marino, P.-L. Lollini, A. Astolfi, G. Pandini, J.A. López-Guerrero, K.L. Schaefer, A. Belfiore, P. Picci & K. Scotlandi. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 30: 2730-2740, 2011. [Medline]
L. Menotti, G. Campadelli-Fiume, P. Nanni, P.-L. Lollini & C. De Giovanni. The molecular basis of herpesviruses as oncolytic agents. Curr. Pharm. Biotechnol., in press, 2011. [Medline]
F. Cavallo, C. De Giovanni, P. Nanni, G. Forni & P.-L. Lollini. 2011: The immune hallmarks of cancer. Cancer Immunol. Immunother., 60: 319-326, 2011. [Medline]
P.-L. Lollini, P. Nanni & C. De Giovanni. Immunotherapy. In: D. Lyden, D.R. Welch, B. Psaila (Eds.), Cancer metastasis: Biologic basis and therapeutics. Cambridge University Press, in press. ISBN: 978-0-521-88721-2
T. Mueck, F. Berger, I. Buechsler, R.S. Valchanova, L. Landuzzi, P.-L. Lollini, K. Klingel & B. Munz. TRAF6 regulates proliferation and differentiation of skeletal myoblasts. Differentiation, 81: 99-106, 2011. [Medline]
E. Bolli, E. Quaglino, M. Arigoni, P.-L. Lollini, R. Calogero, G. Forni & F. Cavallo. Oncoantigens for an immune prevention of cancer. Am. J. Cancer Res., 1: 255-264, 2011. [Medline]
G. Campadelli-Fiume, L. Menotti, G. Zhou, C. De Giovanni, P. Nanni & P.-L. Lollini. Herpesviruses as oncolytic agents. In: J.A. Blaho & J.D. Baines (Eds.). From the hallowed halls of herpesvirology - A tribute to Bernard Roizman. World Scientific Publishing, in press.

2010

A. Palladini, G. Nicoletti, F. Pappalardo, A. Murgo, V. Grosso, V. Stivani, M.L. Ianzano, A. Antognoli, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, S. Motta & P.-L. Lollini. In silico modeling and in vivo efficacy of cancer preventive vaccinations. Cancer Res., 70: 7755-7763, 2010. [Medline]
S. Croci, C.V. Recktenwald, R. Lichtenfels, G. Nicoletti, S.P. Dressler, C. De Giovanni, A. Astolfi, A. Palladini, K. Shin-ya, L. Landuzzi, P. Nanni, P.-L. Lollini & B. Seliger. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics, 10: 3835-3853, 2010.[Medline]
M.A. Pantaleo, G. Nicoletti, C. Nanni, C. Gnocchi, L. Landuzzi, C. Quarta, S. Boschi, M. Nannini, M. Di Battista, P. Castellucci, S. Fanti , P.-L. Lollini, E. Bellan, M. Castelli, D. Rubello & G. Biasco. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J. Exp Clin. Cancer Res., 29: 173, 2010.[Medline]
F. Pappalardo, M. Pennisi, A. Cincotti, F. Chiacchio, S. Motta & P.-L. Lollini. Cancer immunoprevention: What can we learn from in silico models? In: D.-S. Huang, M. McGinnity, L. Heutte, X.-P. Zhang (Eds.), Advanced intelligent computing theories and applications, (Communications in computer and information science Vol. 93), p. 111-118, Springer, Berlin-Heidelberg, 2010.
P.-L. Lollini, G. Nicoletti, L. Landuzzi, C. De Giovanni & P. Nanni. Immunoprevention and immunotherapy of mammary carcinoma. Breast Journal, 16 Suppl 1:S39-41, 2010.[Medline]
M. Pennisi, F. Pappalardo, A. Palladini, G. Nicoletti, P. Nanni, P.-L. Lollini & S. Motta. Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics, 11 Suppl 7: S13, 2010.[Medline]
M. Maio, H.J. Nicolay, P.A. Ascierto, F. Belardelli, R. Camerini, M.P. Colombo, P. Queirolo, R. Ridolfi, V. Russo, E. Fonsatti, G. Parmiani & NIBIT. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. Cancer Immunol. Immunother., 59: 963-969, 2010. Published online Mar. 28 2009. [Medline]
A. Astolfi, P.-L. Lollini, S. Motta, F. Pappalardo. Current issues in tumor immunology. Curr. Bioinform, 5: 164-175, 2010.
M. Halling-Brown, F. Pappalardo, N. Rapin, P. Zhang, D. Alemani, A. Emerson, F. Castiglione, P. Duroux, M. Pennisi, O. Miotto, D. Churchill, E. Rossi, D. Moss, C. Sansom, M. Bernaschi, M.P. Lefranc, S. Brunak, O. Lund, S. Motta, P.-L. Lollini, A. Murgo, A. Palladini, K. Basford, V. Brusic & A.J. Shepherd. ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale. Phil. Trans. R. Soc. A, 368: 2799-2815, 2010. [Medline]
E. Quaglino, C. Mastini, A. Amici, C. Marchini, M. Iezzi, S. Lanzardo, C. De Giovanni, M. Montani, P.-L. Lollini, G. Masucci, G. Forni & F. Cavallo. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res., 70: 2604-2612, 2010. [Medline]
P. Nanni, G. Nicoletti, L. Landuzzi, S. Croci, A. Murgo, A. Palladini, A. Antognoli, M.L. Ianzano, V. Stivani, V. Grosso, S.-M. Maira, C. García-Echeverría, K. Scotlandi, C. De Giovanni, & P.-L. Lollini. High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic drug therapy. Eur. J. Cancer, 46: 659-668. 2010. [Medline]
A. Rocchi, M.C. Manara, M. Sciandra, D. Zambelli, F. Nardi, G. Nicoletti, C. Garofalo, S. Meschini, A. Astolfi, M.P. Colombo, S.L. Lessnik, P. Picci & K. Scotlandi. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest. 120: 668-680, 2010. [Medline]
F. Pappalardo, M.-P. Lefranc, P.-L. Lollini & S. Motta. A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY. Immunome Res., 6: 1, 18 Feb 2010. [Medline]
M.C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni, L. Landuzzi, P.-L. Lollini, S.-M. Maira, C. Garcìa-Echeverrìa, M. Mercuri & P. Picci. NVE-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res., 16: 530-540, 2010. [Medline]
A. Pantaleo, E. Mishani, C. Nanni, L. Landuzzi, S. Boschi, G. Nicoletti, S. Dissoki, P. Paterini, P.P. Piccaluga, F. Lodi, P.-L. Lollini, S. Fanti & G. Biasco. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol. Imaging Biol., 12: 616-625, 2010. [Medline]
D. Zambelli, M. Zuntini, F. Nardi, M.C. Manara, M. Serra, L. Landuzzi, P.-L. Lollini, S. Ferrari, M. Alberghini, A. Llombart-Bosch, E. Piccolo, S. Iacobelli, P. Picci & K. Scotlandi. Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int. J. Cancer, 126: 41-52, 2010. Published online June 19, 2009. [Medline]

2009

P. Nanni, G. Nicoletti, A. Palladini, A. Astolfi, P. Rinella, S. Croci, L. Landuzzi, G. Monduzzi, V. Stivani, A. Antognoli, A. Murgo, M.L. Ianzano, C. De Giovanni & P.-L. Lollini. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol. Cancer Ther., 8: 754-761, 2009. [Medline]
L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P.-L. Lollini & G. Campadelli-Fiume. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc. Natl. Acad. Sci. USA, 106: 9039-9044, 2009. [Medline]
F Pappalardo, M Halling-Brown, N Rapin, P Zhang, D Alemani, A Emerson, P Paci, P Duroux, M Pennisi, A Palladini, O Miotto, D Churchill, E. Rossi, A Shepherd, D Moss, F Castiglione, M Bernaschi, M Lefranc, S Brunak, S Motta, P Lollini, K Basford, V Brusic. ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization. Brief. Bioinform., 10: 330-340, 2009. [Medline]
C. De Giovanni, L. Landuzzi, G. Nicoletti, P.-L. Lollini & P. Nanni. Molecular and cellular biology of rhabdomyosarcoma. Future Oncology, 5: 1449-1475, 2009. [Medline]
S. Misra, V.C. Hascall, C. De Giovanni, R.R. Markwald & S. Ghatak. Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. J. Biol Chem., 284: 12432-12446, 2009. [Medline]
M.A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini & G. Biasco. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann. Oncol., 20: 213-226, 2009. Published online October 7, 2008. [Medline]
G. Nicoletti, A. Palladini, A. Murgo, A. Antognoli, S. Croci, F. Pappalardo, S. Motta & P.-L. Lollini. Translational immunomics of cancer prevention. In A. Falus (Ed.), Clinical applications of immunomics, Springer, New York, 2009, pp 253-268. ISBN: 978-0-387-79207-1 [DOI]
M.A. Pantaleo, L. Landuzzi, G. Nicoletti, C. Nanni, S. Boschi, G. Piazzi, D. Santini, M. Di Battista, P. Castellucci, F. Lodi, S. Fanti, P.-L. Lollini & G. Biasco. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the Gastrointestinal Stromal Tumors (GISTs) model. Clin. Exp. Med, 9: 199-205, 2009. [Medline]
C. De Giovanni, G. Nicoletti, L. Landuzzi, S. Croci, A. Palladini, A. Antognoli, A. Murgo, M.L. Ianzano, V. Grosso, V. Stivani, M. Iezzi, P. Musiani, P. Nanni & P.-L. Lollini. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. Vaccine, 27: 2065-2069, 2009. [Medline]
M.A. Pantaleo, M. Nannini, S. Fanti, S. Boschi, P.-L. Lollini & G. Biasco. Molecular imaging of EGFr: it’s time to go beyond the receptor expression. J. Nucl. Med, 50: 1195-1196, 2009. [Medline]
P.-L. Lollini, L. Menotti, C. De Giovanni, G. Campadelli-Fiume & P. Nanni. Oncolytic herpes virus retargeted to HER-2. Cell Cycle, 8: 2859-2860, 2009. [Medline]
S. Sale, I.L. Fong, C. De Giovanni, L. Landuzzi, K. Brown, W.P. Steward & A.J. Gescher. APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. Eur. J. Cancer, 45: 2731-2735, 2009. [Medline]
C. De Giovanni, G. Nicoletti, A. Palladini, S. Croci, L. Landuzzi, A. Antognoli, A. Murgo, A. Astolfi, S. Ferrini, M. Fabbi, A.M. Orengo, A. Amici, M. L. Penichet, L. Aurisicchio, M. Iezzi, P. Musiani, P. Nanni & P.-L. Lollini. A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome. Hum. Gene Ther., 20: 453-464, 2009. [Medline]

2008

P.-L. Lollini & P. Nanni. Immunoprevention of cancer. In: M. Schwab (Ed.), Encyclopedia of Cancer, 2nd ed. Springer, Heidelberg, 2008, pp 1500-1503. ISBN: 978-3-540-36847-2. [DOI]
P.-L. Lollini, A. Palladini, F. Pappalardo & S. Motta. Predictive models in tumor immunology. In: N. Bellomo, M. Chaplain, E. De Angelis (Eds.), Selected topics in cancer modeling: Genesis, evolution, immune competion, and therapy. Birkhauser, Boston, 2008, pp 363-384. ISBN: 978-0-8176-4712-4 [DOI]
Ehlers, T. Mueck, S. Adams, L. Landuzzi, P.-L. Lollini & B. Munz. RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. Eur. J. Cell. Biol., 8: 163-72, 2008.[Medline]
S. Motta, F. Pappalardo & P.-L. Lollini. Modeling vaccine protocols. In: R.J. Hosking, E. Venturino (Eds.), Aspects of mathematical modeling: Applications in science, medicine, economics and management. Birkhauser, Basel, 2008. ISBN: 978-3-7643-8590-3 [DOI]
A.C. Berardi, S. Marsilio, C. Rofani, O. Salvucci, P. Altavista, F.M. Perla, F. Diomedi-Camassei, S. Uccini, G. Kokai, L. Landuzzi, H.P. McDowell & C. Dominici. Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res., 28: 763-769, 2008. [Medline]

2007

P. Nanni, G. Nicoletti, A. Palladini, S. Croci, A. Murgo, A. Antognoli, L. Landuzzi, M. Fabbi, S. Ferrini, P. Musiani, M. Iezzi, C. De Giovanni & P.-L. Lollini. Antimetastatic activity of a preventive cancer vaccine. Cancer Res., 67: 11037-11044, 2007. [Medline]
M.A. Pantaleo, S. Fanti, P.-L. Lollini, S. Boschi & G. Biasco. PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? Eur. J. Nucl. Med. Mol. Imaging 34: 1510-1511, 2007.[Medline]
F. Pappalardo, S. Motta, P.-L. Lollini, E. Mastriani & M. Pennisi. Towards a personalized schedule with triplex vaccine. Lecture Notes in Computer Science, 4578: 620-626, 2007. [DOI]
S. Croci, G. Nicoletti, L. Landuzzi, A. Palladini, F. Chiarini, P. Nanni, P.-L. Lollini & C. De Giovanni. Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 18: 451-456, 2007.[Medline]
S. Croci, L. Landuzzi, G. Nicoletti, A. Palladini, A. Antognoli, C. De Giovanni, P. Nanni, & P.-L. Lollini. Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. Pathol. Oncol. Res., 13: 336-9, 2007.[Medline]
K. Scotlandi, G. Bernard, M.C. Manara, M. Zuntini, M. Sciandra, A. Rocchi, G. Nicoletti, P. Nanni, P.-L. Lollini, A. Bernard & P. Picci. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene, 26: 6604-6618, 2007. [Medline]
C. De Giovanni, S. Croci, G. Nicoletti, L. Landuzzi, A. Palladini, T. Pannellini, L. Borgia, M. Iezzi, E. Di Carlo, A.M. Orengo, R.C. Kennedy, P.-L. Lollini, P. Nanni & P. Musiani. Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. Int. J. Cancer, 121: 88-94, 2007.[Medline]
M.C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P.L. Lollini, C. Nanni, F. Hofmann, C. García-Echeverría, P. Picci & K. Scotlandi. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. Clin. Cancer Res., 13: 1322-1330, 2007.[Medline]
P.-L. Lollini. Immunologia dei tumori. In C. Caruso, F. Licastro (Eds.), "Compendio di Patologia Generale", Casa Editrice Ambrosiana, Milano, 2007, pp 251-259.
F. Pappalardo, S. Motta, P.-L. Lollini & E. Mastriani. Analysis of vaccine’s schedules using models. Cell. Immunol., 244: 137-40, 2006. [Medline]

2006

P.-L. Lollini, S. Motta & F. Pappalardo. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator. BMC Bioinformatics, 7: 352, 2006. [Medline]
F. Pappalardo, S. Motta, P.-L. Lollini & E. Mastriani. Analysis of vaccine’s schedules using models. Cell. Immunol., 244: 137-40, 2006. Published online 16 April 2007.[Medline]
P.-L. Lollini, S. Motta & F. Pappalardo. Modeling tumor immunology. Math. Mod. Meth. Appl. Sci., 16: 1091-1124, 2006.
P.-L. Lollini, F. Cavallo, P. Nanni & G. Forni. Vaccines for tumour prevention. Nat. Rev. Cancer, 6: 204-216, 2006. [Medline]
T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P.-L. Lollini, G. Forni, F. Cavallo & P. Musiani. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant negative p53 makes their growth independent of HER-2/neu expression. J. Immunol., 176: 7695-7703, 2006. [Medline]
F. Pappalardo, E. Mastriani, P.-L. Lollini & S. Motta. Genetic algorithm against cancer. Lecture Notes in Computer Science, 3849: 223-228, 2006.
P. Nanni, C. De Giovanni & P.-L. Lollini. Cancer biology, what we know and what we don't know. In G. Biasco, S. Tanneberger (Eds.), "Cancer medicine at the dawn of the 21st century: The view from Bologna. Bononia University Press, 2006, pp. 21-47.
A. Comes, O. Rosso, A.M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M.P. Colombo & S. Ferrini. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol., 176: 1750-1758, 2006. [Medline]
M.C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, M.P. Colombo, A. Bernard, P. Picci & K. Scotlandi. CD99 acts as an oncosuppressor in osteosarcoma. Mol. Biol. Cell, 17: 1910-1921, 2006. [Medline]
S. Benini, M. Zuntini, M.C. Manara, P. Cohen, G. Nicoletti, P. Nanni, Y. Oh, P. Picci & K. Scotlandi. Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. Int. J. Cancer, 119: 1039-1046. [Medline]
K. Scotlandi, S. Perdichizzi, G. Bernard, G. Nicoletti, P. Nanni, P.-L. Lollini, A. Curti, M. C. Manara, S. Benini, A. Bernard & P. Picci. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma. Eur. J. Cancer, 42, 91-96, 2006. [Medline]
A. Palladini, A. Astolfi, S. Croci, C. De Giovanni, G. Nicoletti, A. Rosolen, F. Sartori, P.-L. Lollini, L. Landuzzi & P. Nanni. Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. Eur. J Cancer, 42: 680-687, 2006. [Medline]

2005

F. Cavallo, A. Astolfi, M. Iezzi, F. Cordero, P.-L. Lollini, G. Forni & R. Calogero. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics, 6 (Suppl. 4): S7, 2005. [Medline]
K. Scotlandi, M.C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, C. García-Echeverría, F. Hofmann & P. Picci. Anti-tumor activity of the insulin-like growth factor-I receptor (IGF-IR) kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res., 65: 3868-3876, 2005. [Medline]
C. Cuadros, A.L. Dominguez, P.-L. Lollini, M. Croft, R.S. Mittler, P. Borgstrom & J. Lustgarten. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induce a T cell mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer, 116: 934-943, 2005. [Medline]
S. Motta, F. castiglione, P.-L. Lollini & F. Pappalardo. Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res., 1: 5 (pp 1-31), 2005. Published online 7 Oct 2005. [Medline]
F. Pappalardo, P.-L. Lollini, F. Castiglione & S. Motta. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics, 21: 2891-2897, 2005. [Medline]
A. Astolfi, L. Landuzzi, G. Nicoletti, C. De Giovanni, S. Croci, A. Palladini, S. Ferrini, M. Iezzi, P. Musiani, F. Cavallo, G. Forni, P. Nanni & P.-L. Lollini. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol., 166: 1205-1216, 2005. [Medline]
F. Casadio, S. Croci, A. D'Errico Grigioni, B. Corti, W.F. Grigioni, L. Landuzzi & P.-L. Lollini. Toward the definition of immunosuppressive regimens with antitumor activity. Transpl. Proc., 37: 2144-2147 2005. [Medline]
P.-L. Lollini, G. Nicoletti, L. Landuzzi, C. De Giovanni & P. Nanni. New target antigens for cancer immunoprevention. Curr. Cancer Drug Targets, 5: 221-228, 2005. [Medline]
S. Croci, PL. Strippoli, L. Bonsi, G.P. Bagnara, G. Guizzunti, R. Sartini, R. Tonelli, C. Messina, L. Pierdomenico & P.L. Lollini. Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas. Gene, 353: 16-22, 2005. Published online 31 May 2005. [Medline]
M. Lo Iacono, F. Cavallo, E. Quaglino, S. Rolla, M. Iezzi, S.M. Pupa, C. De Giovanni, P.-L. Lollini, P. Musiani, G. Forni & R.A. Calogero. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. Int. J. Immunopathol. Pharmacol., 18: 351-363, 2005. [Medline]
P.-L. Lollini Terapia genica. In G. Cantelli Forti, P. Hrelia (Eds.), "Le biotecnologie e la qualità della vita", Patron Editore, Bologna, 2005.
P.-L. Lollini. Immune response to tumor. In: H.-W. Vohr (ed.), Encyclopedic reference of immunotoxicology, Springer, Heidelberg, 2005. pp 670-674.
A. Astolfi, S. Rolla, P. Nanni, E. Quaglino, C. De Giovanni, M. Iezzi, P. Musiani, G. Forni, P.-L. Lollini, F. Cavallo & R. Calogero. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: A microarray scenario. Cancer Immunol. Immunother., 54: 599-610 2005. [Medline]
P.-L. Lollini, C. De Giovanni, T. Pannellini, F. Cavallo, G. Forni & P. Nanni. Cancer immunoprevention. Future Oncol. 1: 57-66, 2005. [Abstract]
M. Spadaro, E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W.Z. Wei, P. Musiani, P.-L. Lollini, F. Cavallo & G. Forni. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neo-adjuvant IL-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res., 11: 1941-1952, 2005. [Medline]

2004

S. Croci, G. Nicoletti, L. Landuzzi, C. De Giovanni, A. Astolfi, C. Marini, E. Di Carlo, P. Musiani, G. Forni, P. Nanni & P.-L. Lollini. Immunological prevention of a multigene cancer syndrome. Cancer Res., 64: 8428-8434, 2004. [Medline]
P. Nanni, L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, P. Musiani, G. Forni & P.-L. Lollini. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol., 173: 2288-2296, 2004. [Medline]
C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, P. Musiani, F. Cavallo, P. Nanni & P.-L. Lollini. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine. Cancer Res., 64: 4001-4009, 2004. [Medline]
S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M.Y. Follo, N. Oliver, C. De Giovanni, P. Nanni & P.-L. Lollini. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res., 64: 1730-1736, 2004. [Medline]
E. Quaglino, S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P.-L. Lollini, S. Lanzardo, G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero, & F. Cavallo. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest., 113: 709-717, 2004. [Medline]
E. Quaglino, M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S.M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, P.-L. Lollini, P. Musiani, G. Forni & F. Cavallo. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res., 64: 2858-2864, 2004. [Medline]
R. Giavazzi, M. Aglietta, A. Astolfi, A. Falanga, A. Fusco, R. Labianca, P.-L. Lollini, C. Lombardo, P.G. Natali, M.A. Pierotti, M. Presta, M. Santoro, G. Taraboletti, G. Zupi & G. Vecchio. Meeting report - 45th annual meeting of the Italian Cancer Society. Tumori, 90: 356-362, 2004.
C. De Giovanni, L. Landuzzi, G. Nicoletti, A. Astolfi, S. Croci, M. Micaroni, P. Nanni & P.-L. Lollini. APC10.1: an Apc^Min/+ intestinal cell line with retention of heterozygosity. Int. J. Cancer, 109: 200-206, 2004. [Medline]
S. Tanzarella, I. Lionello, B. Valentinis, V. Russo, P.-L. Lollini & C. Traversari. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. Cancer Immunol. Immunother., 53: 519-524, 2004. [Medline]

2003

P. Nanni, G. Nicoletti, C. De Giovanni, S. Croci, A. Astolfi, L. Landuzzi, E. Di Carlo, M. Iezzi, P. Musiani & P.-L. Lollini. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res., 63: 2728-2732, 2003. [Medline]
P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, M. Iezzi, C. Ricci, A. Astolfi, S. Croci, F. Marangoni, P. Musiani, G. Forni & P.-L. Lollini. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int. J. Cancer, 105: 384-389, 2003. [Medline]
C. Curcio, E. Di Carlo, R. Clynes, M.J. Smyth, K. Boggio, E. Quaglino, M. Spadaro, M.P. Colombo, A. Amici, P.-L. Lollini, P. Musiani & G. Forni. Nonredundant roles of antibody, cytokines and perforin for the immune eradication of established Her-2/neu carcinomas. J. Clin. Invest., 111: 1161-1170, 2003. [Medline]
J.S. Dela Cruz, S.Y. Lau, E.M. Ramirez, C. De Giovanni, G. Forni, S.L. Morrison & M.L. Penichet. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine, 21: 1317-1326, 2003. [Medline]
K. Scotlandi, M.C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, F. Bertoni, P. Nanni & P. Picci. c-Kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J. Clin. Oncol., 21: 1952-1960, 2003. [Medline]
P. Cappello, F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P.-L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli & G. Forni. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res., 63: 2518-2525, 2003. [Medline]
P.-L. Lollini. Perspectives in immunotherapy. Suppl. Tumori, 2: S11-S12, 2003.
A. Rosato, S. Dalla Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni & P. Zanovello. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary carcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res., 63: 2158-2163, 2003. [Medline]
P.-L. Lollini & G. Forni. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol., 24: 62-66, 2003. [Medline]
G. Forni, C. Curcio, M. Spadaro, J. Iliffe, E. Quaglino, E. Di Carlo, P. Musiani & P.-L. Lollini. Immunization in tumor prevention. Int. Immunopharmacol., 3: 1151-1158, 2003. [Medline]

2002

P.-L. Lollini, C. De Giovanni, G. Nicoletti, E. Di Carlo, P. Musiani, P. Nanni & G. Forni. Immunoprevention of colorectal cancer: A future possibility? Gastroenterol. Clin. N. Am., 31: 1001-1014, 2002. [Medline]
K. Scotlandi, S. Avnet, S. Benini, M.C. Manara, M. Serra, V. Cerisano, S. Perdichizzi, P.-L. Lollini, C. De Giovanni, L. Landuzzi & P. Picci. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer, 101: 11-16, 2002 [Medline]
P.-L. Lollini & G. Forni. Antitumor vaccines: Is it possible to prevent a tumor? Cancer Immunol. Immunother., 51: 409-416, 2002.[Medline]
C. Ricci, L. Polito, P. Nanni, L. Landuzzi, A. Astolfi, G. Nicoletti, I. Rossi, C. De Giovanni, A. Bolognesi & P.-L. Lollini. HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J. Immunother., 25: 314-323, 2002 [Medline]
P.-L. Lollini. M.A. Pierotti, C. Gambacorti Passerini, M.R. Bani, G. Zupi, M. Aglietta & A. Albini. 28th meeting of the Italian Cancer Society (SIC). New challenges of molecular oncology. Tumori, 88: 77-81, 2002. [Medline]
K. Scotlandi, C. Maini, M.C. Manara, S. Benini, M. Serra, V. Cerisano, R. Strammiello, N. Baldini, P.-L. Lollini, P. Nanni, G. Nicoletti & P. Picci. Effectiveness of Insulin-like growth factor receptor I antisense strategy against Ewing’s sarcoma cells: preclinical evaluation. Cancer Gene Ther., 9: 296-307, 2002. [Medline]
M.C. Manara, B. Perbal, S. Benini, R. Strammiello, V. Cerisano, S. Perdichizzi, M. Serra, A. Astolfi, F. Bertoni, J. Alami, H. Yeger, P. Picci & K. Scotlandi. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 160: 849-859, 2002. [Medline]
P.-L. Lollini. Medicina postgenomica. I Fiori del Maalox, 4: 9-11, 2002
E. Quaglino, S. Rovero, F. Cavallo, P. Musiani, A. Amici, G. Nicoletti, P. Nanni & G. Forni. Immunological prevention of spontaneous tumors: a new prospect? Immunol. Lett., 80: 75-79, 2002. [Medline]

2001

P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S.M. Pupa, I. Rossi, M.P. Colombo, C. Ricci, A. Astolfi, P. Musiani, G. Forni & P.-L. Lollini. Combined allogeneic tumor cell vaccination and systemic IL-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med., 194: 1195:1205, 2001. [Medline]
F. Cavallo, E. Di Carlo, E. Quaglino, M. Iezzi, M. Strasly, F. Bussolino, M.P. Colombo, P. Nanni, P.-L. Lollini, P. Musiani & G. Forni. Prevention by delay: Nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. J. Biol. Regul. Homeost. Agents, 15 351-358, 2001. [Medline]
C. De Giovanni, G. Nicoletti, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, E. Di Carlo, P. Musiani, G. Forni, D. Fradelizi, P. Nanni & P.-L. Lollini. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma. Gene Ther., 8: 1698-1704, 2001. [Medline]
P.-L. Lollini. Terapia genica dei tumori, stato dell'arte e prospettive. Pathologica, 93: 625-630, 2001. [Medline]
A. Astolfi, C. De Giovanni, L. Landuzzi, G. Nicoletti, C. Ricci, S. Croci, L. Scopece, P. Nanni & P.-L. Lollini. Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene, 274: 139-149, 2001. [Medline]
S. Benini, M.C. Manara, N. Baldini, V. Cerisano, M. Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci & K. Scotlandi. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicn against Ewing's sarcoma cells. Clin. Cancer. Res., 7: 1790-1797, 2001. [Medline]
P.-L. Lollini, C. De Giovanni, P. Nanni. Terapia genica. Zanichelli, Bologna, 2001.
A. Astolfi, P. Nanni, L. Landuzzi, C. Ricci, G. Nicoletti, I. Rossi, P.-L. Lollini & C. De Giovanni. An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma. Eur. J. Cancer, 37: 1719-1725, 2001. [Medline]
L. Cifaldi, E. Quaglino, E. Di Carlo, P. Musiani, M. Spadaro, P.-L. Lollini, S. Wolf, K. Boggio, G. Forni & F. Cavallo. A light, nontoxic IL-12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res., 61: 2809-2812, 2001. [Medline]
S.M. Pupa, A.M. Invernizzi, S. Forti, E. Di Carlo, P. Musiani, P. Nanni, P.-L. Lollini, R. Meazza, S. Ferrini & S. Menard. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther., 8: 75-79, 2001. [Medline]
E. Di Carlo, G. Forni, P.-L. Lollini, M.P. Colombo, A. Modesti & P. Musiani. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97: 339-345, 2001. [Medline]
P.-L. Lollini & G. Forni. Progressione tumorale ed immunoprevenzione del cancro. In: F. Dammacco, A. Ferranini & A. Tursi (eds), Allergologia ed immunologia: dalla biologia alla clinica, Monduzzi Editore, Bologna, 2001, pp. 139-143. Atti del Congresso della Società Italiana di Allergologia ed Immunologia Clinica, Bari, 27-30/9/2000.
P.-L. Lollini & G. Forni. Terapia genica: modelli animali. In: D. Amadori & S. Grilli (eds.), Oncologia genetica, Poletto Editore, Milano, 2001, pp. 161-187.

2000

F.A. Scholl, P. McLoughlin, E. Ehler, C. De Giovanni & B.W. Schäfer. DRAL is a p53-responsive gene whose four and a half lim domain protein product induces apoptosis. J. Cell Biol., 151: 495-506, 2000. [Medline]
E. Frascella, E. Lenzini, B.W. Schafer, L. Brecevic, E. Dorigo, L. Toffolatti, P. Nanni, C. De Giovanni & A. Rosolen. Concomitant amplification and expression of PAX7-FKHR and MYCN in a human rhabdomyosarcoma cell line carrying a cryptic t(1;13)(p36;q14). Cancer Genet. Cytogenet., 121: 139-145, 2000. [Medline]
C. De Giovanni, P. Nanni & G. Forni. The prospects for cancer gene therapy. Int. J. Immunopharmacol., 22: 1025-1032, 2000. [Medline]
L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G.P. Bagnara, P. Nanni & P.-L. Lollini. The metastatic ability of Ewing's sarcoma cells is modulated by Stem Cell Factor and by its receptor c-kit. Am. J. Pathol., 17: 2123-2131, 2000. [Medline]
S. Rovero, A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, L. Landuzzi, M.P. Colombo, M. Giovarelli, P. Musiani & G. Forni. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol., 165: 5133-5142, 2000. [Medline]
K. Scotlandi, N. Baldini, V. Cerisano, M.C. Manara, S. Benini, M. Serra, P.-L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, A. Bernard & P. Picci. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res., 60: 5134-5142, 2000. [Medline]
R. Meazza, P.-L. Lollini, P. Nanni, C. De Giovanni, A. Gaggero, A. Comes, M. Cilli, E. Di Carlo, S. Ferrini & P. Musiani. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer, 87: 574-581, 2000. [Medline]
G. Forni, P.-L. Lollini, P. Musiani & M.P. Colombo. Immunoprevention of cancer: Is the time ripe? Cancer Res., 60: 2571-2575, 2000. [Medline]
M. Giovarelli, P. Cappello, G. Forni, T. Salcedo, P.A. Moore, D. W. LeFleur, B. Nardelli, E. Di Carlo, P.-L. Lollini, S. Ruben, S. Ullrich, G. Garotta & P. Musiani. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of antigen presenting cells, lymphocytes and granulocytes. J. Immunol, 164: 3200-3206, 2000. [Medline]
K. Scotlandi, S. Benini, M.C. Manara, M. Serra, P. Nanni, P.-L. Lollini, G. Nicoletti, L. Landuzzi, T. Chano, P. Picci & N. Baldini. A murine model for skeletal metastases of Ewing's sarcoma. J. Orthopaed. Res., 18: 959-966, 2000. [Medline]
P. Nanni, S.M. Pupa, G. Nicoletti, C. De Giovanni, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, R. De Vecchi, A.M. Invernizzi, E. Di Carlo, P. Musiani, G. Forni, S. Menard & P.-L. Lollini. p185 protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer, 87: 186-194, 2000. [Medline]
C. Ricci, L. Landuzzi, I. Rossi, C. De Giovanni, G. Nicoletti, A. Astolfi, S. Pupa, S. Menard, K. Scotlandi, P. Nanni & P.-L. Lollini. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by Glial Growth Factor 2 in human rhabdomyosarcoma cells. Int. J. Cancer, 87: 29-36, 2000. [Medline]
M.C. Manara, N. Baldini, M. Serra, P.-L. Lollini, C. De Giovanni, M. Vaccari, A. Argnani, S. Benini, D. Maurici, P. Picci & K. Scotlandi. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone, 26: 215-220, 2000. [Medline]
K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P.-L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani & G. Forni. Ability of systemic IL-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res., 60: 359-364. [Medline]
S. Ménard, P. Aiello, E. Tagliabue, C Rumio, P.-L. Lollini, M.-I. Colnaghi & A. Balsari. Tamoxifen chemoprevention of hormone-independent tumor in proto-neu-transgenic mice Cancer Res., 60: 273-275, 2000. [Medline]

Publications 1994-1999

Home page